HENDERSON, NV / ACCESSWIRE / November 8, 2018 / A major stem cell report was released today. Scientists have created a tiny, biodegradable scaffold to transplant stem cells and deliver drugs, which may help treat Alzheimer’s and Parkinson’s diseases, aging brain degeneration, spinal cord injuries and traumatic brain injuries. Stem cell transplantation, which shows promise as a treatment for central nervous system diseases, has been hampered by low cell survival rates, incomplete differentiation of cells and limited growth of neural connections.
Our favorite stem cell company in the market right now is BioRestorative Therapies, Inc. (BRTX) a life sciences company focused on stem cell-based therapies. BRTX has been receiving positive findings on their lead cell therapy candidate BRTX-100. With stem cells in the news, stem cell plays could heat up. Everyone should start researching this undiscovered company right away, BRTX (BioRestorative Therapies, Inc.). BRTX is on the cusp of receiving increased attention from the street. As BRTX prepares for its Phase 2 clinical trial using BRTX-100 to treat chronic lumbar disc disease, the company is flying under the radar currently, but that could all change in the blink of an eye. BRTX presents an incredible opportunity to investors that will have discovered the company before BRTX starts its phase 2 clinical trial using BRTX-100.
Companies to put on your radar include: BioRestorative Therapies, Inc. (BRTX), Emerald Health Therapeutics, Inc. (OTCQX:EMHTF), Khiron Life Sciences Corp. (KHRNF), The Green Organic Dutchman Holdings Ltd. (OTCQX:TGODF) and Aphria, Inc. (NYSE:APHA).
BioRestorative Therapies, Inc. (BRTX)
Market Cap: $10.16M Share Price: $1.13
BioRestorative Therapies, Inc. (BRTX), a life sciences company focused on stem cell-based therapies, announced the appointment of Lance Alstodt as Executive Vice President and Chief Strategy Officer. In this capacity, Mr. Alstodt will be responsible for developing and refining the Company’s overall strategy and implementing investment decisions. Mr. Alstodt brings over 25 years of experience in operations, strategy and mergers & acquisitions.
Emerald Health Therapeutics, Inc. (EMHTF)
Market Cap: $490.26M Share Price: $3.61
Emerald Health Therapeutics, Inc. (EMHTF) filed 17 provisional US patent applications covering Emerald’s unique Defined Dose? cannabis dosage forms and formulations. Based on proprietary Emerald research, these patent applications are contributing to Emerald’s intellectual property portfolio and its intent to develop distinctive cannabis products for medical-use and improved adult-use. The products provide more precise and consistent delivery, dosage, and formulations. Defined Dose? cannabis products will, when made available to the public, provide consumers with products currently not available.
Khiron Life Sciences Corp. (KHRNF)
Market Cap: $87.81M Share Price: $1.35
Khiron Life Sciences Corp. (KHRNF), an integrated medical cannabis company with its core operations in Colombia , announced that the Company has extended an agreement with Farmalisto, the regions leading digital drugstore, to market and distribute the Company’s Kuida® CBD cosmeceutical brand to a population of over 120 million consumers in Mexico , subject to approvals from the Federal Commission for the Protection of Health Risks (COFEPRIS).
Aphria, Inc. (APHA)
Market Cap: $3.29B Share Price: $12.72
Aphria Inc. (APHA) announced an agreement with Rapid Dose Therapeutics Inc. that grants the Company with exclusive global preferred rights to license, manufacture, distribute and sell RDT’s QuickStrip? innovative, proprietary delivery technology for both medical and adult-use cannabis market.
The Green Organic Dutchman Holdings Ltd. (TGODF)
Market Cap: $954.19M Share Price: $3.68
The Green Organic Dutchman Holdings Ltd. announced two strategic appointments within its leadership team, with Emily Demeo joining as Marketing Brand Director and Terry Reid joining as Director, Legal and Compliance.
Important Disclaimer, Please Read:
The securities, investments, and industries referenced and impacted in the attached content, are risky investments, that can result in significant or entire loss. This article is not advice in making any speculative investment decision.
The attached content may include predictions, estimates or other information that might be considered forward-looking. While such forward-looking statements represent best judgment on what the future holds, at the time of first publishing, they are subject to risks and uncertainties that could cause actual results to differ materially. You are cautioned not to place undue reliance on any forward-looking statements, that may be found in the attached content, as they only reflect as of the date of first publishing. Please keep in mind that authors, producers, disseminators are not obligated to revise or publicly release the results of any revision to any forward-looking statement, that may be found in the attached content, in light of new information or future events.
Regal Consulting LLC is hired by certain companies to increase awareness and disseminate material public information regarding the paying company. BRTX has paid, and continues to pay Regal to disseminate truthful and potentially material information regarding BRTX.
Regal Consulting LLC is not registered with FINRA or any other financial or securities regulatory authority, and does not provide investment advice. The attached content is not investment advice. Regal Consulting LLC is not a broker dealer.
Before making investment decisions, everyone, including viewers of this content, should seek advice and perform deep and thorough research.
Regal Consulting, LLC. may buy or sell additional shares of any company named, referenced, or impacted by information in the attached content, on the open market at any time, including before, during or after the publishing of the content. The amount of stock Regal may own in BRTX can be found updated here: http://www.regalconsultingllc.com/disclaimer/.
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC, which owns Microcapspeculators.com, is not registered with Finra or any other financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC [and/or] Microcapspeculators.com does not have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC, which owns Microcapspeculators.com, is compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. ACR Communication, LLC has been compensated one thousand dollars cash for this article and twenty four thousand dollars total by Regal Consulting. LLC, for news commentary articles for BRTX. BRTX and Regal Consulting, LLC were given an opportunity to edit information included in this article. This article is based solely on public information and the opinions of ACR Communication, LLC, which believes the news commentary to include accurate and complete information. We may buy or sell additional shares of BRTX in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.
For Full Legal Disclaimer Click Here.
Regal Consulting, LLC,For Full Legal Disclaimer Click Here.
SOURCE: ACR Communication, LLC